CRBP

NASD Corbus Pharmaceuticals Holdings Inc

Oct 27, 2026 · 2:13 AM ET EOD Market Closed

$3.99 ↑ +0.00 (+0.00%) Trading Up from the previous close of $3.99, $0.09 below the day’s high of $4.08

YTD change: -50.98%
vs 20-day SMA: -24.19%
vs 200-day SMA: -54.25%

Price ranges

Previous day

$3.93 $4.08

open $4.08 close $4.05

-$0.03 (-0.74%)

Today

$3.87 $4.08

open $4.05 now $3.99

-$0.06 (-1.48%)

Past week

$3.93 $4.68

from $4.52 now $3.99

-$0.53 (-11.73%)

Past month

$3.93 $7.18

from $7.14 now $3.99

-$3.15 (-44.12%)

This year

$3.87 $12.88

from $8.14 now $3.99

-$4.15 (-50.98%)

Price & Performance

-6.09 (-60.42%) / 6M

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Poor

The stock is 98.7% away from all-time highs of $315.00
CRBP is down 51% since the beginning of the year
CRBP is down 76% over the past 12 months
CRBP is down 44% over the past 1 month
16% of all CRBP investors are betting against CRBP

CRBP reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -76.5%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No

EPS $-1.81

Earnings momentum -49.1% Quarterly EPS growth

Quarterly change -49.1%

Valuation

P/E ratio N/A

Enterprise value $-35075900.0

Beta 1.85

Balance sheet & scale

IncomeN/A

RevenueN/A

Cash$117.9M

Debt$4.3K

Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD

Sector Manufacturing

Sub Sector Chemical Manufacturing

Market cap $77.2M

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFÃŸ expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

Competitor comparison

Ticker	Company	Price	Change
LLY	Eli Lilly and Company	$1,279.14	+0.45%
JNJ	Johnson & Johnson	$266.30	+0.94%
ABBV	AbbVie, Inc.	$286.74	+0.39%
MRK	Merck & Co., Inc.	$140.61	-3.21%
RHHBY	Roche Holding Ltd Sponsored ADR	$59.98	-1.95%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.